Novartis Pharmaceuticals

This study is testing whether secukinumab, an injectable medication, can reduce symptoms of moderate to severe hidradenitis suppurativa (HS) in Chinese adults. HS is a chronic, painful skin condition that causes lumps and sores. The study will follow 36 participants for about a y…

This study is testing an investigational drug called atrasentan in children and teenagers (ages 2 to 18) who have a kidney disease called IgA nephropathy. The main goal is to see if the drug safely reduces the amount of protein in the urine, which is a key sign of kidney damage. …

This study is testing whether adding an investigational drug called ianalumab to a standard ITP medication (TPO-RA) is safe and tolerable for adults with primary immune thrombocytopenia. The main goal is to see if patients can handle the combination treatment and if it helps them…

This early-stage study aims to check the safety and measure how the body processes a new experimental drug called HJB647 for people with chronic heart failure. It will involve about 12 participants who will receive the drug or a placebo for three days while staying in a clinic fo…

This study aims to gather real-world evidence on the safety and effectiveness of a one-time spinal injection gene therapy (ITVISMA®) for people with Spinal Muscular Atrophy (SMA). It will follow 36 U.S. participants, aged 2 and older, for at least a year after their treatment to …

This study aims to understand the best long-term treatment approaches for children and teenagers with specific types of juvenile arthritis (ERA or JPsA) who are taking the drug secukinumab and have achieved inactive disease. Researchers will use data from a German registry to see…

This study aims to see how well a newer combination blood pressure medication (ARNi) works compared to standard single-drug treatments in everyday medical practice. It will involve 500 adults in the United Arab Emirates who have high blood pressure. Researchers will track changes…

This study allows participants who benefited from remibrutinib in previous Novartis trials to continue taking the medication for up to three years. It aims to collect long-term safety data on the drug. The study is open to people with skin or allergy conditions who cannot access …

This study is testing a drug called asciminib in children and teenagers (ages 1 to under 18) with a specific type of chronic blood cancer called Philadelphia-positive chronic myeloid leukemia (CML). The goal is to see if the drug is safe and effective for kids, including those ne…

This small, early-stage study aims to check if adding a new drug called pelabresib to a standard medication (ruxolitinib) is safe for Japanese adults with myelofibrosis, a rare and serious bone marrow cancer. It will involve about 6 participants who are already taking a stable do…

This study aims to see how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) in everyday Italian clinics. It will follow about 50 adult patients for up to two years to see if the treatment helps raise their hemoglobin levels and allows them t…

This study is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for adults with myelofibrosis, a serious bone marrow cancer. It will enroll 460 patients who have not yet tried JAK inhibitor drugs. The main goals are to see if…

This study aims to monitor the safety and effectiveness of the drug Iptacopan (Fabhalta®) in real-world medical settings in Korea. It will follow about 21 adult patients who have been diagnosed with either Paroxysmal Nocturnal Hemoglobinuria (PNH, a rare blood disease) or C3 Glom…

This study aims to see if a new once-daily inhaler containing three medicines (QVM149) works better and is as safe as a common twice-daily inhaler for controlling asthma in teenagers. It will involve about 304 participants aged 12 to 18 whose asthma is not fully controlled on the…

This study is testing whether an investigational drug called zigakibart can slow the progression of IgA nephropathy, a kidney disease. It will involve 32 adults who will receive the drug for two years while researchers check their kidney tissue and function. The main goal is to s…

This study is testing a new combination of drugs for children and young adults (ages 1-30) whose acute lymphoblastic leukemia (ALL) has come back or hasn't responded to other treatments. The goal is to see if adding a new targeted drug (asciminib) to a lower-dose chemotherapy and…

This early-stage study aims to understand how liver function affects the way the body processes an experimental cancer drug called pelabresib. It will enroll 24 adults with advanced cancer, comparing those with normal liver function to those with moderate or severe liver impairme…

This study will analyze the medical records of 14,000 Chinese patients with advanced HR+/HER2- breast cancer to understand how they are treated in real-world hospitals. Researchers will look at which drugs are used first, how long treatments last, and what side effects occur, wit…

This study aims to understand how patients with IgA nephropathy (a kidney disease) respond to two newer medications, iptacopan or atrasentan, in real-world clinical practice. It will follow 80 adult patients in China for 24 months to collect information on their health, treatment…

This study aims to understand how a specific treatment for metastatic prostate cancer is used in real-world medical practice. It will observe about 750 patients who have already received the drug, collecting data on their treatment patterns, side effects, and health outcomes. The…

This early-stage study aims to understand how a new cancer drug called pelabresib interacts with three common medications: a diabetes drug, a sedative, and a birth control pill. Researchers will enroll 24 adults with advanced cancers who have run out of standard treatment options…

This study aims to understand how doctors in China actually prescribe the drug omalizumab for adults with chronic hives (urticaria) in everyday practice. It will review the health records of about 2,500 patients to see what doses are used, how long treatment lasts, and what other…

This study aims to understand if secukinumab, a standard treatment for moderate-to-severe hidradenitis suppurativa (a painful skin condition), has any effect on the progression of plaque in the heart's arteries. It will follow 34 adults who are already at high risk for heart dise…

This study will observe 83 adults with a rare kidney disease called C3 glomerulopathy (C3G) who are already taking the approved drug iptacopan. Researchers will review patients' medical records from before and after starting the medication to understand who gets treated and how t…

This study looks back at real-world data to see how well patients in Japan with high cholesterol stick to their prescribed injection treatments over one year. It compares two different injectable medications, inclisiran and evolocumab, to see which one patients are more likely to…

This study aims to understand how chronic myeloid leukemia (CML) has been treated in Kuwait over the last ten years. Researchers will look at the medical records of 400 adult patients to see what treatments they received, how other health conditions affected their care, and what …

This study aims to understand if a specific CAR-T cell therapy (tisagenlecleucel) could be linked to patients developing a second, different type of T-cell cancer later on. It will analyze existing tissue and blood samples from about 30 people who received the therapy and were la…